Tamsin K Phillips1, Ira B Wilson2, Kirsty Brittain1, Allison Zerbe3, Claude A Mellins4, Robert H Remien4, Catherine Orrell5, Elaine J Abrams3,6, Landon Myer1. 1. Division of Epidemiology and Biostatistics, Centre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa. 2. Department of Health Services, Policy and Practice, Brown University School of Public Health, Providence, RI. 3. ICAP at Columbia University, Mailman School of Public Health, Columbia University, New York, NY. 4. HIV Center for Clinical and Behavioral Studies, New York State Psychiatric Institute, Columbia University, New York, NY. 5. Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine and Department of Medicine, University of Cape Town, Cape Town, South Africa. 6. Vagelos College of Physicians & Surgeons, Columbia University, New York, NY.
Abstract
INTRODUCTION: Routine HIV viral load (VL) monitoring is recommended for patients on antiretroviral therapy, but frequent VL testing, required in pregnant and postpartum women, is often not feasible. Self-reported adherence can be valuable, but little is known about its longitudinal characteristics. METHODS: We followed women living with HIV from antiretroviral therapy initiation in pregnancy through 18-month postpartum in Cape Town, South Africa, with repeated measurement of VL and self-reported adherence using a 3-item scale. We used generalized estimating equations [with results presented as odds ratios (ORs) with 95% confidence intervals (CIs)] to investigate the association between viremia and change in adherence over pairs of consecutive visits. RESULTS: Among 2085 visit pairs from 433 women, a decrease in self-reported adherence relative to the previous visit on any of the 3 self-report items, or the combined scale, was associated with VL >50 and >1000 copies per milliliter. The best-performing thresholds to predict VL >50 copies per milliliter were a single-level decrease on the Likert response item "how good a job did you do at taking your HIV medicines in the way that you were supposed to?" (OR 2.08, 95% CI: 1.48 to 2.91), and a decrease equivalent to ≥5 missed doses or a one-level decrease in score on either of 2 Likert items (OR 1.34, 95% CI: 1.06 to 1.69). CONCLUSIONS: Longitudinal changes in self-reported adherence can help identify patients with viremia. This approach warrants consideration in settings where frequent VL monitoring or other objective adherence measures are not possible.
INTRODUCTION: Routine HIV viral load (VL) monitoring is recommended for patients on antiretroviral therapy, but frequent VL testing, required in pregnant and postpartum women, is often not feasible. Self-reported adherence can be valuable, but little is known about its longitudinal characteristics. METHODS: We followed women living with HIV from antiretroviral therapy initiation in pregnancy through 18-month postpartum in Cape Town, South Africa, with repeated measurement of VL and self-reported adherence using a 3-item scale. We used generalized estimating equations [with results presented as odds ratios (ORs) with 95% confidence intervals (CIs)] to investigate the association between viremia and change in adherence over pairs of consecutive visits. RESULTS: Among 2085 visit pairs from 433 women, a decrease in self-reported adherence relative to the previous visit on any of the 3 self-report items, or the combined scale, was associated with VL >50 and >1000 copies per milliliter. The best-performing thresholds to predict VL >50 copies per milliliter were a single-level decrease on the Likert response item "how good a job did you do at taking your HIV medicines in the way that you were supposed to?" (OR 2.08, 95% CI: 1.48 to 2.91), and a decrease equivalent to ≥5 missed doses or a one-level decrease in score on either of 2 Likert items (OR 1.34, 95% CI: 1.06 to 1.69). CONCLUSIONS: Longitudinal changes in self-reported adherence can help identify patients with viremia. This approach warrants consideration in settings where frequent VL monitoring or other objective adherence measures are not possible.
Authors: Honghu Liu; Loren G Miller; Ron D Hays; Carol E Golin; Tongtong Wu; Neil S Wenger; Andrew H Kaplan Journal: J Acquir Immune Defic Syndr Date: 2006-03 Impact factor: 3.731
Authors: Tamsin Phillips; Kirsty Brittain; Claude A Mellins; Allison Zerbe; Robert H Remien; Elaine J Abrams; Landon Myer; Ira B Wilson Journal: AIDS Behav Date: 2017-02
Authors: Christina Psaros; Jocelyn E Remmert; David R Bangsberg; Steven A Safren; Jennifer A Smit Journal: Curr HIV/AIDS Rep Date: 2015-03 Impact factor: 5.071
Authors: Cynthia A Kleeberger; Jennifer Buechner; Frank Palella; Roger Detels; Sharon Riddler; Rebecca Godfrey; Lisa P Jacobson Journal: AIDS Date: 2004-03-05 Impact factor: 4.177
Authors: Shirley Lecher; Dennis Ellenberger; Andrea A Kim; Peter N Fonjungo; Simon Agolory; Marie Yolande Borget; Laura Broyles; Sergio Carmona; Geoffrey Chipungu; Kevin M De Cock; Varough Deyde; Marie Downer; Sundeep Gupta; Jonathan E Kaplan; Charles Kiyaga; Nancy Knight; William MacLeod; Boniface Makumbi; Hellen Muttai; Christina Mwangi; Jane W Mwangi; Michael Mwasekaga; Lucy W Ng'Ang'A; Yogan Pillay; Abdoulaye Sarr; Souleymane Sawadogo; Daniel Singer; Wendy Stevens; Christiane Adje Toure; John Nkengasong Journal: MMWR Morb Mortal Wkly Rep Date: 2015-11-27 Impact factor: 17.586
Authors: Andreas D Haas; Malango T Msukwa; Matthias Egger; Lyson Tenthani; Hannock Tweya; Andreas Jahn; Oliver J Gadabu; Kali Tal; Luisa Salazar-Vizcaya; Janne Estill; Adrian Spoerri; Nozgechi Phiri; Frank Chimbwandira; Joep J van Oosterhout; Olivia Keiser Journal: Clin Infect Dis Date: 2016-07-26 Impact factor: 9.079
Authors: Tessa Concepcion; Jennifer Velloza; Christopher G Kemp; Amritha Bhat; Ian M Bennett; Deepa Rao; Christina S Polyak; Julie A Ake; Allahna Esber; Nicole Dear; Jonah Maswai; John Owuoth; Valentine Sing'oei; Emmanuel Bahemana; Michael Iroezindu; Hannah Kibuuka; Pamela Y Collins Journal: AIDS Behav Date: 2022-10-09
Authors: Zahra Reynolds; Suzanne M McCluskey; Mahomed Yunus S Moosa; Rebecca F Gilbert; Selvan Pillay; Isaac Aturinda; Kevin L Ard; Winnie Muyindike; Nicholas Musinguzi; Godfrey Masette; Pravi Moodley; Jaysingh Brijkumar; Tamlyn Rautenberg; Gavin George; Brent A Johnson; Rajesh T Gandhi; Henry Sunpath; Vincent C Marconi; Mwebesa Bosco Bwana; Mark J Siedner Journal: HIV Med Date: 2021-11-09 Impact factor: 3.094
Authors: Megan Landes; Monique van Lettow; Ernest Nkhoma; Beth Tippett Barr; Zinenani Truwah; Erik Shouten; Andreas Jahn; Andrew Auld; Thokozani Kalua; Joep J van Oosterhout Journal: J Int AIDS Soc Date: 2019-06 Impact factor: 5.396
Authors: Jennifer M Belus; Alastair van Heerden; Heidi van Rooyen; Valerie D Bradley; Jessica F Magidson; Abigail C Hines; Ruanne V Barnabas Journal: Contemp Clin Trials Commun Date: 2022-08-18
Authors: Nobubelo Kwanele Ngandu; Carl J Lombard; Thandiwe Elsie Mbira; Adrian Puren; Catriona Waitt; Andrew J Prendergast; Thorkild Tylleskär; Philippe Van de Perre; Ameena Ebrahim Goga Journal: BMJ Open Date: 2022-03-10 Impact factor: 2.692